KEWAUNEE SCIENTIFIC CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KEWAUNEE SCIENTIFIC CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Apr 30, 2017 | $138.56M | Jul 21, 2017 |
| FY2016 | Apr 30, 2016 | $128.63M | Jul 21, 2016 |
| FY2016 | Apr 30, 2015 | $118.83M | Jul 21, 2016 |
| FY2014 | Apr 30, 2014 | $0 | Jul 18, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $240.47M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $203.76M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $219.49M | Jun 28, 2024 |
| FY2022 | Apr 30, 2022 | $49.72M | Jul 1, 2022 |
| FY2022 | Jan 31, 2022 | $40.63M | Jul 1, 2022 |
| FY2022 | Oct 31, 2021 | $39.03M | Jul 1, 2022 |
| FY2022 | Jul 31, 2021 | $39.49M | Jul 1, 2022 |
| FY2022 | Apr 30, 2021 | $38.71M | Jul 1, 2022 |
| FY2022 | Jan 31, 2021 | $33.34M | Jul 1, 2022 |
| FY2022 | Oct 31, 2020 | $39.00M | Jul 1, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Apr 30, 2017 | $34.58M | Jul 21, 2017 |
| FY2017 | Jan 31, 2017 | $30.37M | Jul 21, 2017 |
| FY2017 | Oct 31, 2016 | $36.33M | Jul 21, 2017 |
| FY2017 | Jul 31, 2016 | $37.28M | Jul 21, 2017 |
| FY2017 | Apr 30, 2016 | $34.09M | Jul 21, 2017 |
| FY2017 | Jan 31, 2016 | $32.41M | Jul 21, 2017 |
| FY2017 | Oct 31, 2015 | $31.04M | Jul 21, 2017 |
| FY2017 | Jul 31, 2015 | $31.09M | Jul 21, 2017 |
| FY2016 | Apr 30, 2015 | $30.28M | Jul 21, 2016 |
| FY2016 | Jan 31, 2015 | $27.75M | Jul 21, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $68.86M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $52.05M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $35.59M | Jun 28, 2024 |
| FY2022 | Apr 30, 2022 | $9.33M | Jul 1, 2022 |
| FY2022 | Jan 31, 2022 | $5.62M | Jul 1, 2022 |
| FY2022 | Oct 31, 2021 | $3.60M | Jul 1, 2022 |
| FY2022 | Jul 31, 2021 | $5.67M | Jul 1, 2022 |
| FY2022 | Apr 30, 2021 | $6.06M | Jul 1, 2022 |
| FY2022 | Jan 31, 2021 | $5.65M | Jul 1, 2022 |
| FY2022 | Oct 31, 2020 | $6.40M | Jul 1, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $11.41M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $18.75M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $738.0K | Jun 28, 2024 |
| FY2022 | Apr 30, 2022 | ($362.0K) | Jul 1, 2022 |
| FY2022 | Jan 31, 2022 | ($1.32M) | Jul 1, 2022 |
| FY2022 | Oct 31, 2021 | ($3.10M) | Jul 1, 2022 |
| FY2022 | Jul 31, 2021 | ($1.35M) | Jul 1, 2022 |
| FY2022 | Apr 30, 2021 | ($2.98M) | Jul 1, 2022 |
| FY2022 | Jan 31, 2021 | $81.0K | Jul 1, 2022 |
| FY2022 | Oct 31, 2020 | ($180.0K) | Jul 1, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $17.76M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $18.28M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $5.36M | Jun 28, 2024 |
| FY2023 | Apr 30, 2022 | ($2.61M) | Jun 30, 2023 |
| FY2022 | Apr 30, 2021 | ($1.32M) | Jul 1, 2022 |
| FY2021 | Apr 30, 2020 | ($2.35M) | Jul 15, 2021 |
| FY2020 | Apr 30, 2019 | $2.11M | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | $9.92M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | $6.54M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | $5.70M | Jul 21, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $919.0K | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $920.0K | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $1.01M | Jun 28, 2024 |
| FY2023 | Apr 30, 2022 | $990.0K | Jun 30, 2023 |
| FY2022 | Apr 30, 2021 | $1.41M | Jul 1, 2022 |
| FY2021 | Apr 30, 2020 | $1.82M | Jul 15, 2021 |
| FY2020 | Apr 30, 2019 | $1.55M | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | $1.54M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | $1.16M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | $1.17M | Jul 21, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $14.78M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $19.56M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | ($3.79M) | Jun 28, 2024 |
| FY2023 | Apr 30, 2022 | ($7.89M) | Jun 30, 2023 |
| FY2022 | Apr 30, 2021 | $912.0K | Jul 1, 2022 |
| FY2021 | Apr 30, 2020 | $4.16M | Jul 15, 2021 |
| FY2020 | Apr 30, 2019 | $2.49M | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | $3.18M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | $11.66M | Jul 20, 2018 |
| FY2018 | Apr 30, 2016 | $7.27M | Jul 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $194.65M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $134.77M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $118.90M | Jun 28, 2024 |
| FY2023 | Apr 30, 2022 | $118.77M | Jun 30, 2023 |
| FY2022 | Apr 30, 2021 | $89.38M | Jul 1, 2022 |
| FY2021 | Apr 30, 2020 | $83.93M | Jul 15, 2021 |
| FY2020 | Apr 30, 2019 | $87.22M | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | $85.08M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | $80.92M | Jul 20, 2018 |
| FY2018 | Apr 30, 2016 | $72.41M | Jul 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $128.41M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $78.56M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $80.41M | Jun 28, 2024 |
| FY2023 | Apr 30, 2022 | $82.59M | Jun 30, 2023 |
| FY2022 | Apr 30, 2021 | $47.90M | Jul 1, 2022 |
| FY2021 | Apr 30, 2020 | $45.23M | Jul 15, 2021 |
| FY2020 | Apr 30, 2019 | $39.52M | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | $36.89M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | $37.66M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | $33.85M | Jul 21, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $64.46M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $54.76M | Jul 2, 2025 |
| FY2025 | Apr 30, 2023 | $37.41M | Jul 2, 2025 |
| FY2024 | Apr 30, 2022 | $35.69M | Jun 28, 2024 |
| FY2023 | Apr 30, 2021 | $41.24M | Jun 30, 2023 |
| FY2022 | Apr 30, 2020 | $38.42M | Jul 1, 2022 |
| FY2021 | Apr 30, 2019 | $47.10M | Jul 15, 2021 |
| FY2020 | Apr 30, 2018 | $47.73M | Jul 27, 2020 |
| FY2019 | Apr 30, 2017 | $43.46M | Jul 11, 2019 |
| FY2018 | Apr 30, 2016 | $38.24M | Jul 20, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $12.49M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $0 | Jul 2, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $58.92M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $47.51M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $28.76M | Jun 28, 2024 |
| FY2023 | Apr 30, 2022 | $28.02M | Jun 30, 2023 |
| FY2022 | Apr 30, 2021 | $34.15M | Jul 1, 2022 |
| FY2021 | Apr 30, 2020 | $37.82M | Jul 15, 2021 |
| FY2020 | Apr 30, 2019 | $43.55M | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | $43.84M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | $39.77M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | $36.83M | Jul 21, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $14.94M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | $23.27M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | $8.08M | Jun 28, 2024 |
| FY2023 | Apr 30, 2022 | $4.43M | Jun 30, 2023 |
| FY2022 | Apr 30, 2021 | $5.21M | Jul 1, 2022 |
| FY2021 | Apr 30, 2020 | $4.37M | Jul 15, 2021 |
| FY2020 | Apr 30, 2019 | $10.65M | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | $9.72M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | $12.51M | Jul 20, 2018 |
| FY2018 | Apr 30, 2016 | $5.22M | Jul 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $37.69M | Jul 2, 2025 |
| FY2023 | Jun 27, 2022 | $0 | Jun 30, 2023 |
| FY2020 | Apr 30, 2020 | $0 | Jul 27, 2020 |
| FY2020 | Apr 30, 2019 | $97.0K | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | $1.26M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | $2.43M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | $3.35M | Jul 21, 2017 |
| FY2016 | Apr 30, 2015 | $3.77M | Jul 21, 2016 |
| FY2015 | Apr 30, 2014 | $4.19M | Jul 20, 2015 |
| FY2014 | Apr 30, 2013 | $3.27M | Jul 18, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 3 | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | 6 | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | 0 | Jun 28, 2024 |
| FY2022 | Apr 30, 2022 | 0 | Jul 1, 2022 |
| FY2022 | Jan 31, 2022 | 0 | Jul 1, 2022 |
| FY2022 | Oct 31, 2021 | (1) | Jul 1, 2022 |
| FY2022 | Jul 31, 2021 | 0 | Jul 1, 2022 |
| FY2022 | Apr 30, 2021 | (1) | Jul 1, 2022 |
| FY2022 | Jan 31, 2021 | 0 | Jul 1, 2022 |
| FY2022 | Oct 31, 2020 | 0 | Jul 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 3 | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | 6 | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | 0 | Jun 28, 2024 |
| FY2022 | Apr 30, 2022 | 0 | Jul 1, 2022 |
| FY2022 | Jan 31, 2022 | 0 | Jul 1, 2022 |
| FY2022 | Oct 31, 2021 | (1) | Jul 1, 2022 |
| FY2022 | Jul 31, 2021 | 0 | Jul 1, 2022 |
| FY2022 | Apr 30, 2021 | (1) | Jul 1, 2022 |
| FY2022 | Jan 31, 2021 | 0 | Jul 1, 2022 |
| FY2022 | Oct 31, 2020 | 0 | Jul 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 2.84M | Jul 2, 2025 |
| FY2025 | Apr 30, 2024 | 2.84M | Jul 2, 2025 |
| FY2024 | Apr 30, 2023 | 2.83M | Jun 28, 2024 |
| FY2023 | Apr 30, 2022 | 2.79M | Jun 30, 2023 |
| FY2022 | Apr 30, 2021 | 2.76M | Jul 1, 2022 |
| FY2021 | Apr 30, 2020 | 2.75M | Jul 15, 2021 |
| FY2020 | Apr 30, 2019 | 2.75M | Jul 27, 2020 |
| FY2019 | Apr 30, 2018 | 2.73M | Jul 11, 2019 |
| FY2018 | Apr 30, 2017 | 2.71M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | 2.69M | Jul 21, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Apr 30, 2021 | $0 | Jul 15, 2021 |
| FY2020 | Apr 30, 2020 | $1.04M | Jul 27, 2020 |
| FY2020 | Apr 30, 2019 | $2.03M | Jul 27, 2020 |